BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Skin cancer AND CCND3, P30281, 896, ENSG00000112576
44 results:

  • 1. Color Doppler Ultrasound Indices as Predictors of Propranolol Response in Infantile Hemangioma: A Prospective Study.
    Pandey V; Bera RN; Diwedi AND; Singh OP; Tiwari P
    Indian Pediatr; 2024 Mar; 61(3):237-242. PubMed ID: 38469839
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. High-risk Prognostic Tumor Features of Squamous Cell Carcinomas in Organ Transplant Recipients Compared With the General Population.
    Pandeya N; Isbel N; Campbell S; Chambers DC; Hopkins P; Soyer HP; Jiyad Z; Plasmeijer EI; Whiteman DC; Olsen CM; Green AC
    JAMA Dermatol; 2023 Aug; 159(8):854-858. PubMed ID: 37314794
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Prognostic model for predicting overall and cancer-specific survival among patients with superficial spreading melanoma: A SEER based study.
    Ji Q; Tang J; Li S; Chen J
    Medicine (Baltimore); 2022 Dec; 101(52):e32521. PubMed ID: 36596029
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
    Guo B; Wang Y; Liu W; Zhang S
    Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: A systematic review and meta-analysis.
    He R; Zhao X; Liu J; Zhou Y; Zhang X; Cheng F
    Medicine (Baltimore); 2022 Oct; 101(41):e30561. PubMed ID: 36254050
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A rapidly growing cutaneous malignant glomus tumor with a ccnd3 mutation.
    Kitz R; Leung O; Royer M
    J Cutan Pathol; 2023 Feb; 50(2):113-117. PubMed ID: 36059094
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. "Location of cutaneous malignant melanoma in Sweden 2004-2018 - mortality and sex differences".
    Önefäldt D; Zommorodi S; Falk Delgado A
    J Plast Reconstr Aesthet Surg; 2022 Sep; 75(9):3398-3405. PubMed ID: 35803850
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Finding reduced Raman spectroscopy fingerprint of skin samples for melanoma diagnosis through machine learning.
    Araújo DC; Veloso AA; de Oliveira Filho RS; Giraud MN; Raniero LJ; Ferreira LM; Bitar RA
    Artif Intell Med; 2021 Oct; 120():102161. PubMed ID: 34629149
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Comparing the characteristics and predicting the survival of patients with head and neck melanoma versus body melanoma: a population-based study.
    Ding Y; Jiang R; Chen Y; Jing J; Yang X; Wu X; Zhang X; Xu J; Xu P; LiuHuang SC; Lu Z
    BMC Cancer; 2021 Apr; 21(1):420. PubMed ID: 33863315
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Sun Exposure Prevention Practices Within U.S. Naval Aviation.
    Lyford WH; Crotty A; Logemann NF
    Mil Med; 2021 Nov; 186(11-12):1169-1175. PubMed ID: 33748855
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Cutaneous Manifestations of EGFR-Inhibitors in African Americans and Treatment Considerations.
    Geisler AN; Noor SJ
    J Drugs Dermatol; 2020 Sep; 19(9):894-896. PubMed ID: 33026750
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
    Mulder EEAP; Dwarkasing JT; Tempel D; van der Spek A; Bosman L; Verver D; Mooyaart AL; van der Veldt AAM; Verhoef C; Nijsten TEC; Grunhagen DJ; Hollestein LM
    Br J Dermatol; 2021 May; 184(5):944-951. PubMed ID: 32844403
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Immunotherapy in sinonasal melanoma: treatment patterns and outcomes compared to cutaneous melanoma.
    Klebaner D; Saddawi-Konefka R; Finegersh A; Yan CH; Califano JA; London NR; Deconde AS; Faraji F
    Int Forum Allergy Rhinol; 2020 Sep; 10(9):1087-1095. PubMed ID: 32623838
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Does very early timing of lymph node surgery after resection of the primary tumour improve the clinical outcome of patients with melanoma?
    Gambichler T; Bünnemann H; Scheel CH; Bechara FG; Stücker M; Stockfleth E; Becker JC
    Clin Exp Dermatol; 2020 Dec; 45(8):1011-1018. PubMed ID: 32422686
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Non-Classic Signs of Sézary Syndrome: A Review.
    Morris L; Tran J; Duvic M
    Am J Clin Dermatol; 2020 Jun; 21(3):383-391. PubMed ID: 31953789
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Intra-Rater Reliability and Agreement of the Indurometer When Used to Assess Mid-Calf Tissue Compressibility Among People Affected by Moderate to Severe Lymphedema in Bangladesh and Ethiopia.
    Douglass J; Mableson H; Martindale S; Karim J; Mahmood AS; Hailekiros F; Kelly-Hope L
    Lymphat Res Biol; 2020 Aug; 18(4):374-380. PubMed ID: 31859599
    [No Abstract]    [Full Text] [Related]  

  • 17. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].
    Fan HJ; Huang C; Su Y; Wang XD; Zhou YC; Duan C; Zhao W; Zhao Q; Jin M; Ma XL
    Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):863-869. PubMed ID: 31665841
    [No Abstract]    [Full Text] [Related]  

  • 18. Increasing incidence and mortality related to liver cancer in Australia: time to turn the tide.
    Cocker F; Chien Yee K; Palmer AJ; de Graaff B
    Aust N Z J Public Health; 2019 Jun; 43(3):267-273. PubMed ID: 30958629
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment.
    Hawkins ML; Rioth MJ; Eguchi MM; Cockburn M
    J Am Acad Dermatol; 2019 Jun; 80(6):1640-1649. PubMed ID: 30654077
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Mohs micrographic surgery versus wide local excision for melanoma in situ: analysis of a nationwide database.
    Phan K; Loya A
    Int J Dermatol; 2019 Jun; 58(6):697-702. PubMed ID: 30604517
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.